Page 29 - JCTR-9-4

Marchand et al. | Journal of Clinical and Translational Research 2023; 9(4): 236-245 245
[24] Coulam CB, Acacio B. Does Immunotherapy for Treatment Cochrane handbook: Cochrane Reviews: Assessing risk
of Reproductive Failure Enhance Live Births? Am J Reprod of bias in included studies. In: Systematic Reviews of
Immunol 2012;67:296-304. Interventions. Ch. 8. United States: John Wiley & Sons;
[25] Singh N, Davis AA, Kumar S, Kriplani A. The Effect of 2011. p. 3-10.
Administration of Intravenous Intralipid on Pregnancy [34] Egger M, Smith GD, Schneider M, Minder C. Bias in
Outcomes in Women with Implantation Failure After IVF/ Meta-Analysis Detected by a Simple, Graphical Test. BMJ
ICSI with Non-donor Oocytes: A Randomised Controlled 2015;14:1-16.
Trial. Eur J Obstet Gynecol Reprod Biol 2019;240:45-51. [35] Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for
[26] El-Khayat W, El Sadek M. Intralipid for Repeated Publication Bias in the Presence of Heterogeneity. Stat
Implantation Failure (RIF): A Randomized Controlled Med 2003;22:2113-26.
Trial. Fertil Steril 2015;104:e26. [36] Moffett A, Colucci F. Uterine NK Cells: Active
[27] Al-Zebeidi J, Agdi M, Lary S, Al-Obaid S, Salim G, Regulators at the Maternal-Fetal Interface. J Clin Investig
Al-Jaroudi D. Effect of Empiric Intravenous Intralipid 2014;124:1872-9.
Therapy on Pregnancy Outcome in Women with [37] Seshadri S, Sunkara SK. Natural Killer Cells in Female
Unexplained Recurrent Implantation Failure Undergoing Infertility and Recurrent Miscarriage: A Systematic Review
Intracytoplasmic Sperm Injection-embryo Transfer Cycle: and Meta-Analysis. Hum Reprod Update 2014;20:429-38.
A Randomized Controlled Trial. Gynecol Endocrinol
2019;36:131-4. [38] Zheng L, Feng Y, Shi Y, Zhang J, Mu Q, Qin L, et al.
[28] Gamaleldin I, Gomaa MF, Shafik A, Akande V. Intralipid Intralipid Decreases Apolipoprotein M Levels and Insulin
Sensitivity in Rats. PLoS One 2014;9:e105681.
Infusion does not Improve Live Birth Rates in Women
with Unexplained Recurrent Implantation Failure and [39] Aviram M, Deckelbaum RJ. Intralipid Infusion into
May Increase the Risk of Congenital Malformations, a Humans Reduces in Vitro Platelet Aggregation and Alters
Double-Blinded Randomised Controlled Trial. BJOG 2018; Platelet Lipid Composition. Metabolism 1989;38:343-7.
125:31-2. [40] Moffett A, Shreeve N. First do no Harm: Uterine Natural
[29] Dakhly DM, Bayoumi YA, Sharkawy M, Allah SH, Killer (NK) Cells in Assisted Reproduction. Hum Reprod
Hassan MA, Gouda HM, et al. Intralipid Supplementation 2015;30:1519-25.
in Women with Recurrent Spontaneous Abortion and [41] Aoki K, Kajiura S, Matsumoto Y, Ogasawara M,
Elevated Levels of Natural Killer Cells. Int J Gynecol Okada S, Yagami Y, et al. Preconceptional Natural-
Obstet 2016;135:324-7. Killer-Cell Activity as a Predictor of Miscarriage. Lancet
[30] Cohen R, Check JH, Wilson C, Choe JK. Intravenous 1995;345:1340-2.
Intralipid Therapy is not Beneficial in Having a Live [42] Habets DH, Schlütter A, van Kuijk SM, Spaanderman ME,
Delivery in Women Aged 40-42 with Previous History Al-Nasiry S, Wieten L. Natural Killer Cell Profiles in
of Miscarriage Undergoing in Vitro Fertilization-Embryo Recurrent Pregnancy Loss: Increased Expression and
Transfer. Fertil Steril 2009;92:S20-1. Positive Associations with TACTILE and LILRB1. Am J
[31] O’Connor D, Green S. Higgins JP Cochrane Handbook for Reprod Immunol 2022;88:e13612.
Systematic Reviews of Interventions: Cochrane Book Series. 43] Practice Committee of the American Society for
Chichester (UK): John Wiley & Sons; 2008. p. 81-94. [Reproductive Medicine. Intravenous Immunoglobulin
[32] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA (IVIG) and Recurrent Spontaneous Pregnancy Loss. Fertil
Group. Preferred Reporting Items for Systematic Reviews Steril 2006;86:S226-7.
and Meta-Analyses: The PRISMA Statement. PLoS Med [44] Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of
2009;6:e1000097. Intravenous Immunoglobulin (IVIG) Therapy. Autoimmun
[33] Green S, Higgins JP, Alderson P, Clarke M, Mulrow DC. Rev 2007;6:257-9.

Publisher’s note
AccScience Publishing remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
DOI: http://dx.doi.org/10.18053/jctres.09.202304.23-00060